AcelRx shares soar on positive, head-to-head pain drug study

AcelRx Pharmaceuticals shares ($ACRX) got a big boost this morning after the biotech announced that its post-operative pain therapy--the Sufentanil NanoTab PCA (patient-controlled analgesia) System--was not only not inferior to the standard IV morphine but also beat it on a key measurement score while gaining kudos from nurses and patients. "With these impressive top-line results from this head-to-head clinical trial, we have successfully completed an important step towards our New Drug Application submission and, dependent on completing the remaining Phase III trials and obtaining FDA approval, eventual commercialization of the Sufentanil NanoTab PCA System," commented Richard King, the CEO of AcelRx Pharmaceuticals. Shares shot up 25%. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.